Novartis Launches Tender Offer to Acquire Regulus Therapeutics in $7 Per Share Deal, with Potential Bonus Payout Linked to Regulatory Milestone In a strategic move that underscores its continued investment in innovative biotechnology, Novartis announced today that its wholly owned…
WHO Launches Landmark Guideline to Bridge Global Gaps in Access to Controlled Medicines In a bold step toward improving global health equity, the World Health Organization (WHO) unveiled a new guideline aimed at helping countries strike a critical balance between…
Eisai’s Lemborexant (DAYVIGO®) Receives Regulatory Approval in China for the Treatment of Insomnia Eisai Co., Ltd., a leading global pharmaceutical company headquartered in Tokyo and led by CEO Haruo Naito, announced a significant milestone in its global expansion strategy with…
Cullinan Therapeutics and Taiho Highlight Promising Phase 2b Results of Zipalertinib in Advanced EGFR ex20ins NSCLC at ASCO 2025 Cullinan Therapeutics,in collaboration with Taiho Pharmaceutical Co., Ltd., and its U.S. affiliate Taiho Oncology, Inc., has announced encouraging new results from…
Bayer Launches Centafore Imaging Core Lab to Revolutionize Clinical Trial Imaging and SaMD Development Bayer, a global leader in healthcare and life sciences, today officially announced the launch of its Imaging Core Lab under the new brand name Centafore™. This…
Dr. Mark Stetter Elected to Zoetis Board of Directors, Bringing Decades of Veterinary Leadership and Animal Health Expertise Zoetis,a global leader in animal health, announced a significant addition to its governance with the election of Dr. Mark Stetter to its…
Bristol Myers Squibb Showcases Expansive Oncology Portfolio and Groundbreaking Clinical Research at ASCO 2025 Annual Meeting Bristol Myers Squibb is set to make a significant impact at the 2025 American Society of Clinical Oncology (ASCO®) Annual Meeting, which will be…
Lilly’s Kisunla (Donanemab) Gains Marketing Authorization in Australia for Early Alzheimer’s Treatment Eli Lilly and Company has announced that the Australian Therapeutic Goods Administration (TGA) has granted marketing authorization for Kisunla (donanemab), a novel treatment for early symptomatic Alzheimer’s disease.…
AstraZeneca Showcases Broad Oncology Leadership with More Than 80 Abstracts and Two Plenary Presentations at ASCO 2025, Reinforcing Ambition to Eliminate Cancer as a Cause of Death AstraZeneca is poised to make a major impact at the 2025 American Society…
Sanofi to Acquire Vigil Neuroscience in $470 Million Deal, Bolstering Neurology Pipeline with Promising Alzheimer’s Drug Candidate In a strategic move that further solidifies its commitment to neurological disorders, Sanofi announced it has entered into a definitive agreement to acquire…
Celltrion’s YUFLYMA® Secures Full FDA Interchangeability Status Across All Approved Forms and Strengths, Reinforcing Market Leadership and Commitment to Affordable Biologics Celltrion, Inc., a global biopharmaceutical company headquartered in South Korea, announced a significant regulatory milestone with the U.S. Food…
Grifols Secures FDA Clearance to Advance Immunoglobulin Eye Drops into Phase 2 Trial for Dry Eye Disease Grifols, a global leader in the production of plasma-derived medicines and a prominent name in the healthcare sector, has taken a pivotal step…